We've updated our Privacy Policy to make it clearer how we use your personal data.

We use cookies to provide you with a better experience. You can read our Cookie Policy here.

Advertisement
Millipore Announces Technology Acquisition to Strengthen Drug Discovery Product Offering
News

Millipore Announces Technology Acquisition to Strengthen Drug Discovery Product Offering

Millipore Announces Technology Acquisition to Strengthen Drug Discovery Product Offering
News

Millipore Announces Technology Acquisition to Strengthen Drug Discovery Product Offering

Read time:
 

Want a FREE PDF version of This News Story?

Complete the form below and we will email you a PDF version of "Millipore Announces Technology Acquisition to Strengthen Drug Discovery Product Offering"

First Name*
Last Name*
Email Address*
Country*
Company Type*
Job Function*
Would you like to receive further email communication from Technology Networks?

Technology Networks Ltd. needs the contact information you provide to us to contact you about our products and services. You may unsubscribe from these communications at any time. For information on how to unsubscribe, as well as our privacy practices and commitment to protecting your privacy, check out our Privacy Policy

Millipore has announced that it has purchased the assets associated with Epitome Biosystems’ EpiTag™ technology. The purchase price was not disclosed.

The technology acquisition will enable Millipore’s Bioscience Division to expand its presence in the fast growing multiplex immunoassay market by offering scientists a broader portfolio of cell signaling assays that can be used with the Luminex xMAP® platform. Additionally, the acquisition will allow for the future development of other novel profiling technologies.

“Our multiplex offering is one of our fastest growing product lines and the acquisition of the EpiTag technology will help us to accelerate our product development and expand our growth prospects in this dynamic market,” said Rick Ryan, Vice President of Millipore’s Drug Discovery Business Unit.

”Our customers are interested in better understanding the roles that cell pathways play in major diseases such as cancer and diabetes. The EpiTag technology will allow us to develop multiplex immunoassays for cellular targets that were previously very difficult to detect and quantify. As a result, we will enable customers to leverage the power of the Luminex xMAP platform for cell signaling by providing antibodies and kits that are specific to the highest areas of interest for researchers,” Ryan said.
Advertisement